Literature DB >> 24177784

Estimation of fish and ω-3 fatty acid intake in pediatric nonalcoholic fatty liver disease.

David E St-Jules1, Corilee A Watters, Elizabeth M Brunt, Lynne R Wilkens, Rachel Novotny, Patricia Belt, Joel E Lavine.   

Abstract

AIMS: Fish and ω-3 fatty acids are reported to be beneficial in pediatric nonalcoholic fatty liver disease (NAFLD), but no studies have assessed their relation to histological severity. The objectives of this study were to evaluate the dietary intake of fish and ω-3 fatty acids in children with biopsy-proven NAFLD, and examine their association with serological and histological indicators of disease.
METHODS: This was a cross-sectional analysis of 223 children (6-18 years) who participated in the Treatment of Nonalcoholic Fatty Liver Disease in Children trial or the NAFLD Database study conducted by the Nonalcoholic Steatohepatitis Clinical Research Network. The distribution of fish and ω-3 fatty acid intake was determined from responses to the Block Brief 2000 Food Frequency Questionnaire, and analyzed for associations with serum alanine aminotransferase, histological features of fatty liver disease, and diagnosis of steatohepatitis after adjusting for demographic, anthropometric, and dietary variables.
RESULTS: The minority of subjects consumed the recommended 8 ounces of fish per week (22/223 [10%]) and 200 mg of long-chain ω-3 fatty acids per day (12/223 [5%]). Lack of fish and long-chain ω-3 fatty acid intake was associated with greater portal (P = 0.03 and P = 0.10, respectively) and lobular inflammation (P = 0.09 and P = 0.004, respectively) after controlling for potential confounders.
CONCLUSIONS: Fish and ω-3 fatty acid intake was insufficient in children with NAFLD, which may increase susceptibility to hepatic inflammation. Patients with pediatric NAFLD should be encouraged to consume the recommended amount of fish per week.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24177784      PMCID: PMC3864540          DOI: 10.1097/MPG.0b013e3182a1df77

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  32 in total

1.  GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects.

Authors:  Da Young Oh; Saswata Talukdar; Eun Ju Bae; Takeshi Imamura; Hidetaka Morinaga; WuQiang Fan; Pingping Li; Wendell J Lu; Steven M Watkins; Jerrold M Olefsky
Journal:  Cell       Date:  2010-09-03       Impact factor: 41.582

2.  Dietary intake of stearidonic acid-enriched soybean oil increases the omega-3 index: randomized, double-blind clinical study of efficacy and safety.

Authors:  Shawna L Lemke; John L Vicini; Hong Su; Daniel A Goldstein; Margaret A Nemeth; Elaine S Krul; William S Harris
Journal:  Am J Clin Nutr       Date:  2010-08-25       Impact factor: 7.045

Review 3.  The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease.

Authors:  Haim Shapiro; Miryam Tehilla; Joelle Attal-Singer; Rafael Bruck; Rachel Luzzatti; Pierre Singer
Journal:  Clin Nutr       Date:  2010-07-08       Impact factor: 7.324

4.  Omega-3 polyunsaturated fatty acids in adolescents: knowledge and consumption.

Authors:  Z Harel; S Riggs; R Vaz; L White; G Menzies
Journal:  J Adolesc Health       Date:  2001-01       Impact factor: 5.012

5.  Dietary intake of fats and fatty acids for the United States population: 1999-2000.

Authors:  R Bethene Ervin; Jacqueline D Wright; Chia-Yih Wang; Jocelyn Kennedy-Stephenson
Journal:  Adv Data       Date:  2004-11-08

6.  Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents.

Authors:  Mehmet Keskin; Selim Kurtoglu; Mustafa Kendirci; M Emre Atabek; Cevat Yazici
Journal:  Pediatrics       Date:  2005-03-01       Impact factor: 7.124

7.  Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease.

Authors:  Julia Araya; Ramón Rodrigo; Luis A Videla; Lilian Thielemann; Myriam Orellana; Paulina Pettinelli; Jaime Poniachik
Journal:  Clin Sci (Lond)       Date:  2004-06       Impact factor: 6.124

8.  Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity.

Authors:  Elisa Fabbrini; Faidon Magkos; B Selma Mohammed; Terri Pietka; Nada A Abumrad; Bruce W Patterson; Adewole Okunade; Samuel Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-24       Impact factor: 11.205

Review 9.  The importance of the ratio of omega-6/omega-3 essential fatty acids.

Authors:  A P Simopoulos
Journal:  Biomed Pharmacother       Date:  2002-10       Impact factor: 6.529

10.  Decreased liver fatty acid delta-6 and delta-5 desaturase activity in obese patients.

Authors:  Julia Araya; Ramón Rodrigo; Paulina Pettinelli; A Verónica Araya; Jaime Poniachik; Luis A Videla
Journal:  Obesity (Silver Spring)       Date:  2009-10-29       Impact factor: 5.002

View more
  12 in total

Review 1.  Role of the diet as a link between oxidative stress and liver diseases.

Authors:  Teresa Arrigo; Salvatore Leonardi; Caterina Cuppari; Sara Manti; Angela Lanzafame; Gabriella D'Angelo; Eloisa Gitto; Lucia Marseglia; Carmelo Salpietro
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

2.  Omega-3 for nonalcoholic fatty liver disease in children.

Authors:  Paul Clerc; Marialena Mouzaki; Ran D Goldman
Journal:  Can Fam Physician       Date:  2019-01       Impact factor: 3.275

3.  Effect of Dietary and Lifestyle Interventions on the Amelioration of NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study.

Authors:  Sofía Montemayor; Cristina Bouzas; Catalina M Mascaró; Miguel Casares; Isabel Llompart; Itziar Abete; Escarlata Angullo-Martinez; María Ángeles Zulet; J Alfredo Martínez; Josep A Tur
Journal:  Nutrients       Date:  2022-05-26       Impact factor: 6.706

Review 4.  Nutrition, nonalcoholic fatty liver disease and the microbiome: recent progress in the field.

Authors:  Miriam B Vos
Journal:  Curr Opin Lipidol       Date:  2014-02       Impact factor: 4.776

Review 5.  Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Valerio Nobili; Anna Alisi; Kimberly P Newton; Jeffrey B Schwimmer
Journal:  Gastroenterology       Date:  2016-03-19       Impact factor: 22.682

Review 6.  Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future.

Authors:  Mehran Rahimlou; Hoda Ahmadnia; Azita Hekmatdoost
Journal:  World J Hepatol       Date:  2015-11-08

Review 7.  Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development.

Authors:  Pau Vancells Lujan; Esther Viñas Esmel; Emilio Sacanella Meseguer
Journal:  Nutrients       Date:  2021-04-24       Impact factor: 5.717

Review 8.  Non-alcoholic fatty liver disease in children: focus on nutritional interventions.

Authors:  Min Yang; Sitang Gong; Shui Qing Ye; Beth Lyman; Lanlan Geng; Peiyu Chen; Ding-You Li
Journal:  Nutrients       Date:  2014-10-28       Impact factor: 5.717

Review 9.  Is there a role of lipid-lowering therapies in the management of fatty liver disease?

Authors:  Ismini Tzanaki; Aris P Agouridis; Michael S Kostapanos
Journal:  World J Hepatol       Date:  2022-01-27

Review 10.  Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease.

Authors:  Gigliola Alberti; Juan Cristóbal Gana; José L Santos
Journal:  Nutrients       Date:  2020-11-17       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.